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Abstract 
 
Background: L-dopa responsiveness in Parkinson’s disease (PD) varies, but the 
clinical correlates and significance of this are ill-defined. 
 
Methods: Patients were assessed before and after their usual morning L-dopa dose, 
using the MDS Unified PD Rating Scale Part 3 (MDS UPDRS 3), and rated as 
definite responders (≥24.5% improvement) or limited responders (<24.5%). 
 
Results: 1007 cases, mean age 66.1 years (SD 9.1) at diagnosis, were assessed 
3.4 (SD 0.9) years after diagnosis. The L-dopa response was definite in 614 cases 
(61.0%), median reduction in MDS UPDRS 3 scores was 42.0%, (IQR 33.3, 53.1), 
and was limited in 393 cases (39.0%), median reduction in MDS UPDRS 3 scores 
11.5% (IQR 4.3, 18.2). Definite responders were younger (66.3 years at study entry, 
SD 9.3) than limited responders (69.2 years, SD 8.4, p<0.001). The MDS UPDRS 3 
score at study entry in definite responders (21.0, SD 10.5) was significantly lower 
than in limited responders (24.7, SD 13.4, p<0.001). The MDS UPDRS 3 increase 
over 18 months was less in definite responders at 3.0 (SD 10.4), compared to limited 
responders (6.4, SD 11.0, p<0.001). The levodopa equivalent daily dose (LEDD) 
was not significantly different at study entry (definite responders 317mg, SD 199, vs 
limited responders 305mg, SD 191, p=0.53). However, LEDD was significantly 
higher at the time of the L-dopa challenge test in definite responders (541mg, SD 
293) compared to limited responders (485mg, SD 215, p=0.01). Responsiveness to 
L-dopa was unaffected by the challenge test dose (p=0.54). 
 
Conclusions: The main determinants of variation in the L-dopa response in early 
PD are age and motor severity. A limited L-dopa response is associated with faster 
motor progression.  
 
 
 
 
 
 
Introduction 
 
The phenotypic heterogeneity of Parkinson’s disease (PD) is well recognized[1], and 
includes variability in L-dopa responsiveness[2, 3]. While an excellent [4] or clear 
and dramatic [5] response to L-dopa is a supportive feature in the diagnostic criteria 
for idiopathic PD, a less marked response does not rule out the diagnosis of PD [4, 
5]. A number of studies have shown variation in the response to either an acute L-
dopa challenge dose [6, 7, 8], or chronic L-dopa therapy [2, 4, 6, 8] both in clinically 
diagnosed PD [2, 4, 6, 8], and in pathologically confirmed cases [4]. However, the 
clinical correlates and significance of this variation in response are not clearly 
defined. We wished to explore in detail, in a large cohort of recently diagnosed 
patients, which clinical characteristics are associated with the level of motor 
responsiveness to L-dopa. We hypothesised that a limited motor response to L-dopa 
was a likely contributor to variation in the motor progression rate, which could be 
measured by prospective observation. We also set out to examine whether 
comorbidities (e.g. cerebrovascular disease) influenced the L-dopa motor response.   
 
Methods  
 
Tracking Parkinson’s is a prospective observational multicentre study that has 
recruited from 72 centres in the United Kingdom (UK). Patients were recruited with a 
clinical diagnosis of PD made by a clinician if they fulfilled UK Brain Bank criteria [4]. 
This was supported by structural and/or functional neuroimaging when the diagnosis 
was not firmly established clinically. Both drug-naïve and treated patients, aged 18 to 
90 years were eligible. Recent onset cases (diagnosed in the preceding 3.5 years), 
were recruited between February 2012 and May 2014. Patients were not enrolled if 
they had severe comorbid illness, other degenerative forms of parkinsonism such as 
multiple system atrophy (MSA), or parkinsonism attributable to significant 
cerebrovascular disease. Patients with drug-induced parkinsonism were excluded, 
but drug-unmasked PD was allowed if justified by abnormal functional dopaminergic 
imaging. Patients whose diagnosis was later revised from PD during regular follow-
up were excluded from any analysis. 
Any features (signs, symptoms, progression, medication response) that were 
possibly unusual or atypical for PD (and might be early pointers to atypical 
parkinsonian disorders such as MSA) were noted at recruitment, and during follow-
up. These cases were included in the main analysis, but excluded from the sub-
analysis. The study was approved by the West of Scotland Ethics Committee, written 
informed consent was obtained from patients, and procedures followed the 
Declaration of Helsinki. The study was supported by funding from Parkinson’s UK. 
The following features were collected in all patients: demographic characteristics, 
diagnostic features at presentation, medication history, Movement Disorder Society 
Unified Parkinson's Disease Rating Scale (MDS UPDRS) scores [9] including part 3 
scores ‘on’ or ‘off’ medication (‘off’ being defined operationally as below), non-motor 
symptom severity scale (NMSS) [10], Rapid eye movement sleep (REM) sleep 
behaviour disorder scale [11] and the Scale for Outcomes in Parkinson's disease for 
Autonomic Symptoms (SCOPA-AUT) [12]. Motor phenoytpe was categorized 
according to defined methods [13]. Montreal cognitive assessment (MoCA) test 
scores were adjusted for years of education. Hyposmia was defined using a Sniffin’ 
Stick score of less than or equal to the 10th centile, or at or below the 15th centile on 
the University of Pennsylvania Smell Test score (British version), corrected for age 
and sex [14]. Presence of low mood and depression was assessed using the Leeds 
Anxiety and Depression Scale (LADS) with a cut-off score >6 [15]. L-dopa equivalent 
daily dose (LEDD) was calculated using an established formula [16].  
Vascular risk was calculated by standard methods, using the QRISK2 algorithm, as 
previously reported [17]. Rheumatoid arthritis was included as a vascular risk 
equivalent, as this confers an increased vascular risk [18]. 
At the 2 year visit an L-dopa challenge test was carried out in patients prescribed L-
dopa based therapy. Patients were asked to omit their usual morning anti-
parkinsonian medication. Those co-prescribed a dopamine agonist omitted this from 
the night before the L-dopa challenge test (for immediate release preparations) and 
the day before (for once-daily preparations). Assessments were undertaken in an 
‘off’ state and was repeated 1 hour after the patient’s usual morning dose of L-dopa, 
expressed as the dose of L-dopa in mg (the L-dopa:decarboxylase ratio was 4:1). 
The change in MDS UDPRS 3 was dichotomised around a 24.5% improvement, 
which is equivalent to the 30% change in the UPDRS 3 score [7] and defined as 
‘definite’ when improvement was ≥24.5%, and ‘limited’ when <24.5%. 
 
Statistical analysis 
A logistic regression model was used with response to L-dopa challenge test as the 
outcome, and the ’limited’ group as the baseline category. Odds ratios, 95% 
confidence intervals and p-values were calculated, before and after adjustment for 
age, gender and disease duration. Sensitivity analysis was implemented for missing 
values in the outcome and clinical variables. MoCA, UPDRS 3, SCOPA-AUT, NMSS, 
olfaction tests scores, and motor responsiveness to L-dopa, were calculated based 
on expected scores, when at least 80% of the questions were answered in each 
scale. Any remaining missing values were then imputed 10 times, using the multiple 
imputation chained equations approach. Odds ratios and p-values were calculated in 
the logistic regression models using Rubin’s rules. Statistical analysis was conducted 
at 5% significance level, using STATA/MP software version 15.1. 
 
Results 
 
There were 2006 patients recruited, of whom 37 were excluded either due to disease 
duration over 3.5 years (n=6) or change in diagnosis after recruitment (n=31). A 
further 429 did not have data for the 2-year visit, leaving 1540 cases, of whom 228 
were not prescribed L-dopa at the time of the visit, and 305 in whom data collection 
was incomplete. Accordingly, complete data were available for the L-dopa challenge 
in 1007 cases (Table 1). 
These cases had a mean age of 67.5 years (SD 9.1) at study entry, and the L-dopa 
response was assessed on average 3.4 years (SD 0.9) after diagnosis. A definite L-
dopa response was seen in 614 cases (61.0%). The mean change in MDS UPDRS 3 
from pre to post challenge L-dopa dose was 42.0% (IQR 33.3, 53.1) in those with a 
definite response, versus 11.5% (IQR 4.3, 18.2) in those with a limited response. 
Patients who showed a definite L-dopa response were younger (66.3 years, SD 9.3) 
compared to those with a limited response (69.2 years, SD 8.4, p<0.001). Those with 
a definite response had a lower MDS UPDRS 3 score at study entry (21.0, SD 10.5) 
than those with a limited response (24.7, SD 13.4, p<0.001) (Figure 2). Further, 
those with a definite response showed a smaller increment in MDS UPDRS 3 scores 
over the next 18 months (increase of 3.0 points, SD 10.4) compared to an increase 
of 6.4 points (SD 11.0) in those with a limited response, p<0.001. The demographic 
and phenotypic characteristics of the cases who undertook the L-dopa challenge test 
are shown in Table 1. Using 24.5 % as the cut-off for defining definite responders 
and limited responders showed a bell-shaped curve (Supplementary Figure 1). The 
LEDD was not significantly different at study entry comparing those with a definite 
response (317mg, SD 199) to those with a limited response (305mg, SD 191, 
p=0.53). However, the LEDD at the time of the challenge test was higher in those 
with a definite response (541mg, SD 293) compared to those with a limited response 
(485mg, SD 215, p=0.01). The proportion of cases with an unequivocal motor 
response was higher in definite responders (25.0%) compared to limited responders 
(17.8%, p=0.0106). More patients classified as definite responders were prescribed 
a monoamine oxidase type B inhibitor (34.0%) than those classified as limited 
responders (27.0%, p=0.0213). The increase in the MDS UPDRS 3 scores in the 
283 cases that were L-dopa naïve at study entry, from baseline to the ‘off’ score prior 
to the challenge test, did not differ significantly when comparing definite responders 
to limited responders (p=0.8, Table 1). There were no statistical differences in 
disease duration, sex, motor subtype, cognitive scores, non-motor scores, hyposmia, 
presence of a rapid eye movement behaviour disorder, constipation, depression or 
autonomic scores between those with a definite versus a limited L-dopa response.  
Considering comorbid vascular disease and vascular risk factors, only 49.4% of the 
89 patients with Type 2 diabetes showed a definite L-dopa response. In patients with 
a prior history of vascular disease (n=149) 53.7% showed a definite L-dopa 
response. Similarly, in patients with high vascular QRISK2 scores (n=345), 56.2% 
had a definite response to L-dopa, compared to 61.6% with medium vascular risk 
scores (n=295), and 72.6% with low vascular risk scores (n=215). However, these 
observations were not statistically significant after adjusting for age, sex, and 
disease duration. There were no significant differences between definite and limited 
responders for any of the following: prior vascular diagnosis (cardiac or cerebral), 
rheumatoid arthritis, body mass index, the presence of orthostatic hypotension, or 
smoking status. 
The mean dose of L-dopa used in the acute challenge test was not significantly 
different between definite and limited responders, whether considering actual dose, 
or dose per kilogram body weight (Table 2). There was also no significant difference 
according to fulfilment of MDS diagnostic criteria for PD, comparing definite and 
limited L-dopa responders (Table 2). 
In the sensitivity analysis all 1312 subjects on L-dopa at the 2-year visit were 
assessed (Figure 1). Missing data were relatively low (<10%), except in SCOPA-
AUT (38.5%), NMSS (22.3%) and L-dopa motor response (23.3%). Results did not 
differ, in any of the key findings, in the sensitivity analysis compared to the main 
analysis (results not shown).  
In the sub-analysis in 949 cases without any unusual or atypical features (94.2% of 
the 1007 cases) the significant findings of the relationship between L-dopa response 
remained: age (p<0.001), motor severity (p<0.001), and motor progression 
(p=0.001).  
 
 
Discussion 
 
Our main finding is that, in a large cohort of prospectively recruited recent onset PD 
patients, there is a substantial variation in the degree of motor response to L-dopa. 
These results are consistent with variation in L-dopa responsiveness in clinical trials 
and pathological case series [2-4]. In the ELLDOPA study in 260 L-dopa treated 
patients, the average improvement in UPDRS 3 was 27.4% (SD 30.6) at 9 weeks, 
and 26.2% (SD 36.4) at 24 weeks [2, 3]. Because of the known differences between 
the UPDRS 3 and MDS UPDRS Part 3 scores [7] the comparable percentage 
improvements in the ELLDOPA study using the MDS UPDRS 3 would give 
improvements of 33.6% (SD 37.5) at 9 weeks and 32.1% (SD 44.6) at 24 weeks. 
Variation in the degree of L-dopa response has also been reported in pathologically 
confirmed PD [4]. In 69 of 76 confirmed PD cases in whom the L-dopa response was 
available, it was graded as definite in 29%, good in 39%, limited in 13%, and nil-to-
poor in 4% [4]. Taken together, we can conclude that the degree of motor 
improvement in response to L-dopa is subject to significant variation, although the 
reasons for this are unclear. We therefore sought to better define what factors may 
be important in determining the level of response. 
 
First we examined demographic and disease related features and found that older 
patients showed a less robust response to L-dopa, which has been observed 
previously [19]. However, we did not confirm the previously reported associations of 
male gender and postural instability with lower L-dopa response rates [2]. We did 
however identify a significant relationship between L-dopa responsiveness and 
baseline motor scores, as well as rates of motor progression over an 18-month 
period. These findings are of clinical significance: patients with lower responsiveness 
to L-dopa have higher motor scores, and faster motor progression. A relationship 
between increasing age and progression of disability has been observed previously, 
and attributed in part to L-dopa non-responsive motor symptoms [20]. Further, we 
observed that more definite responders were prescribed monoamine oxidase type B 
inhibitors, compared to limited responders, which is in keeping with mechanisms and 
responses for this drug class [21]. 
 
Secondly, given our previous finding of higher motor scores and more cognitive 
problems in patients with vascular disease, or increased vascular risk factors [17], 
and the known association of vascular disease with age, we examined for any 
relationship between vascular comorbidity and L-dopa response in the present study. 
While we found that both diabetes and higher vascular risk scores were associated 
with lower L-dopa responsiveness, these observations were driven by patient age, 
so we can conclude that vascular comorbidity is not an independent driver of an 
impaired L-dopa response. 
 
There are several other potential explanations for variation in L-dopa 
responsiveness. Diagnostic inaccuracy is known to occur in cases with an early 
clinical diagnosis of PD [4, 5], and a poor or absent L-dopa responses in such 
erroneously diagnosed cases would affect the response levels reported. We 
controlled for this confounding factor in 2 ways, firstly by prospective collection of 
structured information of individual clinical features that might be atypical for PD, with  
analysis after excluding these cases, and secondly by considering the L-dopa 
response in relation to fulfilment of MDS diagnostic criteria [22]. We did not find 
major differences using either approach, compared to the main analysis: an 
additional 1.3% of cases had a definite response after excluding possible atypical 
features, while there was no indication of differences in L-dopa response according 
to categorisation by MDS criteria into ‘established PD’ or ‘probable PD’, versus those 
not fulfilling PD criteria. Taken together, it appears that diagnostic error is not a major 
contributor to the variation observed in L-dopa responsiveness in our study. 
 
The dose of L-dopa used to assess responsiveness is clearly important and is 
another source of variation in our study and others. We used the patient’s standard 
morning L-dopa dose in the acute challenge test, which may have underestimated 
the response to L-dopa in some cases. However, we reasoned that this relatively 
lower dose was appropriate, as it would be better tolerated by patients. Furthermore 
it is an approach that has been adopted in other similar observational studies [23], 
and in fact we found that the dose used in our challenge tests was not significantly 
different between definite and limited responders. However, the LEDD at the time of 
the challenge test was significantly lower (around 50mg per day) in patients with a 
limited response compared to those with a definite response, while there was no 
difference in LEDD between the groups at study entry. This raises the possibility that 
some patients are under-dosed despite worsening motor severity. Other factors may 
influence the drug dose given to some patients, such as neuropsychiatric features 
[24]. Our findings suggest that clinicians are more likely to increase dopamine 
replacement therapy doses when there is a stronger L-dopa response.  
 
Earlier literature reported acute challenge tests with higher L-dopa doses. For 
example, a unit dose of 250mg L-dopa gave a positive response (i.e. a reduction in 
motor score equivalent to the threshold used in the present report) in 39 of 55 early 
PD cases (70.9%) [8]. An earlier systematic review of dopaminergic challenge tests 
in PD, which included 2 studies using acute L-dopa challenges, calculated that 69% 
of de novo PD and 76% of established PD exceeded this same threshold of 
response, but this combined results using 250mg L-dopa in 45 cases, 200mg L-dopa  
in 1 case, and 100mg L-dopa in 21 cases [25]. Direct comparison with our findings is 
difficult, as those previous studies used a mixture of tasks and degrees of 
improvement to assess response (e.g. walking speed, tapping tasks, and 15-20% 
improvement in motor scores) and only 1 of the 4 studies assessed the acute L-dopa 
challenge response using UPDRS 3 scores [25]. Assessing the effect of escalating 
L-dopa challenge test doses is the subject of few reports: in one study 16 out of 22 
cases (72.7%) responded at 100mg L-dopa, which increased by 1 case (to 77.2%) 
when the L-dopa challenge dose was increased to 200mg [26]. Further support of 
the impact of the L-dopa dose comes from the ELLDOPA study [3]. Considering 
those cases that had more than a 10% improvement in motor score after 24 weeks 
of L-dopa treatment compared to baseline, this accounted for 76.5% of cases 
prescribed 300mg L-dopa per day, compared to 89% of cases prescribed 600mg L-
dopa per day [2].  
 
The other major consideration in L-dopa responsiveness relates to known inter-
subject variability in its pharmacokinetics. Variations in body weight [27], gut 
absorption [28] and gender [29] are all reported as potential contributors to response 
variations. The known higher bioavailability of L-dopa in postmenopausal women 
[29] did not, however, translate to a gender differences in our study. There are 
several other biological mechanisms that influence pharmacokinetics and 
pharmacodynamics of L-dopa at the cellular level. Higher levels of erythrocyte 
catechol-O-methyltransferase (which catabolises L-dopa) may impair the L-dopa 
response [30], and genetic variants of this [31] and other enzymes, including dopa 
decarboxylase [32] and monoamine oxidase type B [31], are emerging as 
contributors to later motor fluctuations associated with L-dopa. We consider it likely 
that genetic influences in the pharmacodynamic and pharmacokinetic handling of L-
dopa will also influence the motor response to this drug even at earlier disease 
stages. The results of these detailed genetic analyses (including data about motor 
complications from our ongoing observations) will be the subject of a later report 
from our group.  
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Figure Legends 
 
Figure 1. Patient recruitment to this study. The main analysis of L-dopa response 
was performed in all cases. Additional analysis was done in those cases without 
features that might be atypical for Parkinson’s disease.  
PD = Parkinson’s disease; MSA=Multiple System Atrophy; PSP = Progressive 
Supranuclear Palsy 
 
 
 
Figure 2. MDS UPDRS 3 score at study entry and 18 months later, according to L-
dopa response measured by challenge test, in 1007 patients with Parkinson’s 
disease. Motor scores were significantly worse in those with a limited response at 
both time points. The increase was also significantly greater in those with a limited 
response, compared to those with a definite response (see text). Data are mean and 
standard deviation; datapoints are offset for clarity. 
MDS UPDRS = Movement Disorder Society Unified Parkinson’s Disease Rating 
Scale. 
 
Supplementary Figure 1. Frequency distribution of L-dopa response. The percentage 
improvement in MDS-UPDRS part 3 scores following L-dopa challenge dosing 
showed a bell-curve. The red vertical line indicates the 24.5% cut-off, above which 
the L-dopa response is considered excellent. 
 
